Ultragenyx Pharmaceutical (NASDAQ:RARE) Reaches New 52-Week Low – Should You Sell?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares hit a new 52-week low during mid-day trading on Monday . The company traded as low as $30.46 and last traded at $31.97, with a volume of 206071 shares traded. The stock had previously closed at $32.43.

Wall Street Analyst Weigh In

Several equities analysts recently commented on RARE shares. Cantor Fitzgerald restated an “overweight” rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Canaccord Genuity Group lifted their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. Wedbush reaffirmed a “neutral” rating and issued a $48.00 target price (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Finally, Piper Sandler reduced their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating on the stock in a research report on Monday, March 17th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $92.79.

Ultragenyx Pharmaceutical Stock Performance

The firm’s 50-day moving average is $40.83 and its two-hundred day moving average is $45.93. The stock has a market cap of $3.02 billion, a P/E ratio of -5.07 and a beta of 0.61.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The firm had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. As a group, research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insider Activity

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 73,434 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $3,091,571.40. Following the completion of the sale, the chief executive officer now owns 641,731 shares of the company’s stock, valued at approximately $27,016,875.10. This represents a 10.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Howard Horn sold 1,785 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the transaction, the chief financial officer now directly owns 106,169 shares in the company, valued at approximately $4,289,227.60. This represents a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 124,643 shares of company stock valued at $5,256,268 in the last 90 days. 5.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RARE. California State Teachers Retirement System increased its holdings in Ultragenyx Pharmaceutical by 0.3% during the 4th quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company’s stock worth $3,284,000 after purchasing an additional 268 shares in the last quarter. Van ECK Associates Corp raised its holdings in shares of Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 273 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of Ultragenyx Pharmaceutical by 1.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock valued at $928,000 after buying an additional 294 shares during the last quarter. BOKF NA lifted its holdings in Ultragenyx Pharmaceutical by 5.0% during the 4th quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company’s stock valued at $336,000 after purchasing an additional 382 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 493 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.